CBIH Pursues Patent for Cannabinoid-Based Therapy Targeting Opioid Addiction Recovery
Key Insights
Cannabis Bioscience International Holdings (search) announced pursuit of a patent for an investigational cannabinoid-based therapy (search) designed to address opioid addiction (search), focusing on the vulnerable post-detoxification recovery phase.
The approach targets reward circuits (search) in the brain and the endocannabinoid system (search) to modulate neural communication, alleviate withdrawal symptoms, and reduce relapse vulnerability during recovery.
With over 700,000 opioid-related deaths since the early 2000s and 54,743 estimated deaths in 2024 alone, the initiative addresses a critical public health crisis affecting tens of thousands annually.
Cannabis Bioscience International Holdings (search), Inc. (OTCID: CBIH (search)) announced it is pursuing a new patent for an investigational therapy designed to address opioid addiction (search) through targeting endocannabinoid pathways. The initiative comes as the opioid crisis continues to devastate communities across the United States, with more than 700,000 people having died from opioid-involved overdoses since the early 2000s.
According to U.S. public health data, an estimated 54,743 Americans died from opioid-related overdoses in 2024 alone, even as overall overdose deaths declined compared to prior years. The persistent severity of the crisis has prompted CBIH (search) to focus its research efforts on what many consider one of the most challenging aspects of addiction treatment: preventing relapse during the recovery phase.
Targeting Critical Recovery Window
"Opioid addiction (search) is not simply a matter of 'willpower' or a single drug--it is a complex, chronic psychiatric and medical condition," said Rosangel Andrades, MD, CBIH (search) R&D Director. "As a health-focused company, we believe it is both a public health priority and a moral obligation to contribute serious, science-based solutions for a community that has often been stigmatized and neglected."
The company's patent initiative focuses specifically on reward circuits (search) in the brain and the endocannabinoid system (search), which is widely expressed in those pathways. Recovery represents one of the most fragile stages in the rehabilitation process, with many individuals who successfully complete detoxification ultimately relapsing during this critical period.
CBIH (search)'s research program centers on this vulnerable post-detox window, seeking to complement existing treatments with cannabinoid-based strategies. The investigational approach aims to support the brain during recovery by exploring three key mechanisms:
- Modulating intercellular communication in key neural circuits
- Alleviating withdrawal-related symptoms
- Reducing vulnerability to relapse by promoting greater neurobiological balance
Scientific Rationale and Approach
From a physiological perspective, opioids bind to receptors in critical regions of the brainstem and can trigger respiratory depression, frequently leading to fatal outcomes. These mechanisms make opioids a "silent killer" whose risk profile varies by molecule but remains consistently severe. Additionally, from a psychiatric standpoint, opioid use disorder (search) significantly increases the risk of other mental and physical comorbidities.
The company's approach seeks to help an "addicted brain" gradually regain stability and resilience during the recovery phase. John Jones, CBIH (search) Treasurer, noted that "this formulation will be presented to Mr. Robert F. Kennedy Jr., Secretary of Health and Human Services, to explore opportunities for potential collaboration in research and to evaluate possible next steps."
Regulatory Environment and Future Outlook
The patent initiative follows President Donald J. Trump's December 18, 2025 Executive Order directing the Attorney General and relevant federal agencies to expedite the completion of the ongoing federal process to reclassify cannabis from Schedule I to Schedule III. The order also calls for expanding medical marijuana and cannabidiol research.
CBIH (search) views this policy direction as an opportunity to expand dialogue with pharmaceutical partners, regulators, and other industry stakeholders to advance compliant clinical research and responsible product development. The company continues to invest in science-first medical cannabis innovation through its formulations and patent portfolio.
"This patent effort is about more than commercial opportunity," Dr. Andrades emphasized. "It is a social and medical commitment: to treat people with opioid use disorder (search) with the same urgency and dignity that we devote to conditions like cancer, diabetes, or heart disease. Stigma should never stand in the way of science, compassion, or care."